FOXA2 was shown to be repressed and hypermethylated in its promoter in lung cancer [25], whereas it was also shown that FOXA2 was activated with hypermethylation in the promoter during endoderm development [39]. This evidence concerns the gene FOXA2 and lung carcinoma.